吡菲尼酮对牛血清蛋白诱导的肝纤维化大鼠肝损害的保护作用观察*

doi:10.3969/j.issn.1672-5069.2015.01.016

Abstract

Abstract: Objective To investigate the impact of pirfenidone on liver fibrosis induced by bovine serum albumin （BSA） in rats and its relevant mechanism. Methods 30 male Wistar rats were randomly divided into three groups: e.g. in control group the rats were given saline intraperitoneally,in model group were given BSA intraperitoneally,and in treatment group were given intragastric administration of pirfenidone at the dose of 200 mg.kg^-1.d^-1 after 5-week intraperitoneal injection of BSA. The animals were sacrificed after 4-week treatment and the liver specimens were collected. Hepatic pathology was performed by haematoxylin-eosin stain and Masson trichrome stain,and the expression of Smad 6 was detected by immunohistochemistry. Results As compared with in model group, the number of cases with liver fibrosis stage of S3-S4 in treatment group decreased, with significantly reduced infiltration of inflammatory cells,narrowed fibrous septum in liver tissues. Relative expression of Smad 6 in model group was significantly lower than that in treatment group [（108.2±33.6） vs. （329.4±39.2）,P<0.05]. Conclusions Pirfenidone can inhibit liver fibrosis induced by BSA in rats,which might be attributed to the upregulation of Smad 6.

Key words: Liver fibrosis, Pirfenidone, Smad6, Rats

Li Ping, Yang Qiuhui, Wang Junling, et al. Inhibition of hepatic fibrosis induced by bovine serum albumin by pirfenidone in rats[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 63-66.

References

[1] Salazar-Montes A,Ruiz-Corro L,Lopez-Reyes A,et al.Potent antioxidant role of pirfenidone in experimental cirrhosis,Eur J Pharmacol,2008,595（1-3）：69-77.
[2] Takeda Y,Tsujino K,Kijima T,et al.Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence,2014,8：361-370.
[3] Conte E,Gili E,Fagone E,et al.Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.Eur J Pharm Sci,2014,58C：13-19.
[4] 唐桂连. 肝星状细胞与肝纤维化.国际消化病杂志,2012,13（5）：270-273.
[5] 王美玲,陆伦根.肝纤维化治疗研究进展.实用肝脏病杂志,2013,16（4）：369-371.
[6] 李旭,齐明华.肝内细胞上皮-间质转化:肝纤维化发生的新机制.世界华人消化杂志,2012,15（10）：811-817.
[7] 中华医学会传染病与寄生虫病学分会和肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,6（6）：324-329.
[8] 陈月桥,毛德文.肝纤维化动物模型制备的研究进展.实用肝脏病杂志,2007,10（3）：205-207.
[9] Di Sario A,Bendia E,Macarri G,et al.The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1（I）,TIMP-1 and MMP-2.Dig Liver Dis,2004,36（11）：744-751.
[10] 李紫琼,郑勇. TIMPs和MMPs与肝纤维化研究进展. 实用肝脏病杂志,2007,10（5）：355-358.
[11] Di Sario A,Bendia E,Svegliati BG,et al.Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production,J Hepatol,2002,37（5）：584-591.
[12] Kaibori M,Yanagida H,Uchida Y,et al.Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats.Transplant Proc,2004,36（7）：1973-1974.
[13] Wang F,Wen T,Chen X Y,et al.Protective effects of pirfenidone on D-galactosamine and lipopolysaccharide-induced acute hepatotoxicity in rats.Inflamm Res,2008,57（4）：183-188.
[14] 李萍,陶立坚,胡国龄,等.1-（3-氟苯基）-5-甲基-2-（1H）吡啶酮对肝星状细胞的影响.中国临床药理学与治疗学,2007,18（7）：782-785.
[15] Lim Y S,Lee H S.The expression of E-cadherin in human and rat hepatic stellate cells:evidence of epithelial-mesenchymal transition.Taehan Kan Hakhoe Chi,2002,8（1）：90-99.
[16] Li Y,Sun Y,Liu F,et al.Correction: norcantharidin inhibits renal interstitial fibrosis by blocking the tubular epithelial-mesenchymal transition. PLoS One,2013,8（10）:e44324.
[17] Srivastava S P,Koya D,Kanasaki K. MicroRNAs in kidney fibrosis and diabetic nephropathy:roles on EMT and EndMT. Biomed Res Int,2013,20（13）：125469.
[18] Desmouliere A,Darby I A,Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab Invest,2003,83（12）：1689-1707.
[19] Zeisberg M,Hanai J,Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med,2003,9（7）：964-968.
[20] Bi WR,Xu GT,Lv LX,et al. The ratio of transforming growth factor-beta1/bone morphogenetic protein-7 in the progression of the epithelial-mesenchymal transition contributes to rat liver fibrosis.Genet Mol Res,2014,13（1）：1005-1014.

Inhibition of hepatic fibrosis induced by bovine serum albumin by pirfenidone in rats

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xu Fei, Li Weirong.. Protective effects of astragaloside in rats with CCL₄-induced liver injuries [J]. Journal of Practical Hepatology, 2019, 22(6): 808-811.
[2]	Gao Lei, Cao Lei, Wang Ruifang, et al.. Protective effect of human umbilical cord mesenchymal stem cell transplantation on alcoholic liver injury in rats [J]. Journal of Practical Hepatology, 2019, 22(6): 812-815.
[3]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[4]	Lin Qiuxiang, Wang Xuewen, Huang Zuxiong, et al. Protective effects of breviscapine on liver and intestinal mucosal barrier functions in rats with hepatic ischemia-reperfusion injury [J]. Journal of Practical Hepatology, 2019, 22(5): 636-639.
[5]	Shi Xiaolong, Du Rui, Qin Geping, et al. Protective effect of sevoflurane on sepsis-induced liver injury in rats [J]. Journal of Practical Hepatology, 2019, 22(5): 640-643.
[6]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[7]	Wang Yan, Su Feng, Li Yuanyuan, et al. Protective effect of bee venom hemolysin on rats with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 474-477.
[8]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[9]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[10]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[11]	Zhou Liyun, Li Xiaotian, Li Li. 1,25（OH）₂D₃ inhibits hepatic fibrosis by regulating miR-146a levels in vitro and in vivo [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 333-336.
[12]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[13]	Guo Liping, Zhang Chenghong, Ning Baoshuo, et al.. An improved approach for seperating hepatocytes from neonatal rats in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 17-20.
[14]	Yusup Tursun, Zhao Yanxia.. Establishment of low-dose diethylnitrosamine-induced liver fibrosis model in rats [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 33-36.
[15]	Guo Xiaoxia, Guo Beiting, Kong Xianglu.. Effects of splenectomy on hepatic fibrosis in mice with poly I:C-induced primary biliary cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 837-841.